

## **Bio-Path Holdings Compassionate Use / Pre-Approval Access Policy**

The team at Bio-Path Holdings is committed to developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company's goal is to develop low-toxicity anticancer therapies that can benefit even those patients who would not historically be eligible for anticancer therapies because of their age or other comorbidities or whose cancers are unresponsive to standard treatment approaches.

Our product candidates are currently in early-to-mid stages of clinical development, and as such their safety and effectiveness have not yet been fully vetted. We are therefore not providing access to our investigational treatments through "compassionate use" or "expanded access" programs at this time. This is a policy that we plan to revisit as our programs advance in clinical development and their activity profiles are better understood.

If you are interested in participating in one of our ongoing clinical trials, we encourage you and your healthcare provider to visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) for a list of available trials.